225
Participants
Start Date
June 15, 2015
Primary Completion Date
February 8, 2019
Study Completion Date
February 18, 2021
LCZ696
The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
Enalapril
The target dose during the study was enalapril 10 mg bid given orally. Enalapril was provided as 2.5 mg, 5 mg, and 10 mg tablets.
Placebo to LCZ696
LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
Placebo to Enalapril
Enalapril Placebo 2.5 mg, 5 mg and 10 mg tablets
Novartis Investigative Site, Saku
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Seto
Novartis Investigative Site, Chikushino-shi
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Iizuka
Novartis Investigative Site, Kurume
Novartis Investigative Site, Fukushima
Novartis Investigative Site, Kōriyama
Novartis Investigative Site, Maebashi
Novartis Investigative Site, Hatsukaichi
Novartis Investigative Site, Asahikawa
Novartis Investigative Site, Otaru
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Amagasaki
Novartis Investigative Site, Takarazuka
Novartis Investigative Site, Morioka
Novartis Investigative Site, Takamatsu
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Kawasaki
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kumamoto
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Uji
Novartis Investigative Site, Sendai
Novartis Investigative Site, Miyazaki
Novartis Investigative Site, Kashihara
Novartis Investigative Site, Ōita
Novartis Investigative Site, Okayama
Novartis Investigative Site, Kishiwada
Novartis Investigative Site, Osaka
Novartis Investigative Site, Osaka
Novartis Investigative Site, Takatsuki
Novartis Investigative Site, Toyonaka
Novartis Investigative Site, Tokorozawa
Novartis Investigative Site, Kusatsu
Novartis Investigative Site, Shizuoka
Novartis Investigative Site, Shimotsuke
Novartis Investigative Site, Bunkyo-ku
Novartis Investigative Site, Chiyoda-ku
Novartis Investigative Site, Chuo Ku
Novartis Investigative Site, Hachiōji
Novartis Investigative Site, Itabashi-ku
Novartis Investigative Site, Shinagawa-ku
Novartis Investigative Site, Yonago
Novartis Investigative Site, Shūnan
Novartis Investigative Site, Kofu
Novartis Investigative Site, Saitama
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY